Application note: Middle-up mass analysis of protease digested cetuximab
Posted: 30 November 2022 | Merck | No comments yet
Protocol for purification, proteolysis, reduction and UHPLC-MS analysis of unlabelled and labelled monoclonal antibodies
This application note details a complete workflow of a middle-up mass analysis of protease digested Cetuximab monoclonal antibody, starting with the antibody purification, proteolysis and reduction to its reversed phase UHPLC-MS analysis.
Related content from this organisation
- Antibody-immunotherapy treatment shows benefit in serious endometrial cancer
- First-in-class biologic approved for rare lung disease
- Mycoplasma testing market expected to value nearly $2 million by 2031
- Pharmaceutical suspension market to witness accelerated growth
- Immunotherapy drug achieves trial-first in fifty years
Related topics
Analytical techniques, Biopharmaceuticals, Formulation, Manufacturing, QA/QC, Research & Development (R&D)
